Ventricular fibrillation treatment market was valued at $15.4 billion in 2025 and is anticipated to reach $29 billion by 2035, growing at a CAGR of 6.0% from 2026 to 2035. Ventricular fibrillation is a dangerous, life-threatening heart rhythm where the heart’s lower chamber shivers instead of pumping blood. This shuddering of the heart leads to cardiac arrest and death for an individual. The advancements in technologies such as innovative cardiac ablation and electrophysiology are driving the growth of the market during the forecast period.
Browse the full report description of “Ventricular Fibrillation Treatment Market Size, Share & Trends Analysis By Diagnostic Techniques (Electrocardiogram, Blood Test, Echocardiogram, Electrophysiology Study, and Others), By Treatment (Cardiopulmonary Resuscitation (CPR), Defibrillation, Pharmacological Therapy, Catheter Ablation, Cardiac Resynchronization Therapy (CRT), Left Cardiac Sympathetic Denervation, and Others), By Route Of Administration (Intravenous (IV), Intraosseous (IO), Oral, and Others), and By End-Users (Hospitals & Clinics, Ambulatory Surgical Centers, and Others) Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/ventricular-fibrillation-treatment-market
The expansion of therapeutic options, along with improving procedural efficiency for patients to reduce the complex arrhythmias which will further boost market growth. For instance, in March 2025, Abbott announced that the company had received the CE mark in Europe for its Volt™ Pulsed Field Ablation System. The system is to treat patients with abnormal heart rhythms. The company also shared that they have begun commercial PFA cases in Europe with physicians who have already gained experience with the Volt PFA System within Abbott's PFA clinical studies. Further, the company revealed that Abbott will further expand the use of Volt in EU markets throughout the second half of the year.
Key Players and Innovations
The key players in the ventricular fibrillation treatment market are Abbott Laboratories, Advanced Instrumentations Inc., Amgen Inc., AstraZeneca PLC, Baxter International Inc., Bexen Cardio, Biotronik SE & Co. KG, Boston Scientific Corp., and CU Medical Systems, Inc., among others. These companies are propelling market growth through strategic initiatives such as the development of advanced implantable cardioverter-defibrillators (ICDs) and wearable cardiac devices, expanding their global presence via partnerships and acquisitions, investing in research and development for next-generation therapies, and adopting digital health solutions for remote monitoring and early arrhythmia detection.
Market Coverage
Key questions addressed by the report.
Global Ventricular Fibrillation Treatment Market Report Segment
By Diagnostic Techniques
By Treatment
By Route Of Administration
By End-Users
Global Ventricular Fibrillation Treatment Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/ventricular-fibrillation-treatment-market